Personalized plan: decide between Ozempic, Wegovy, or compounded semaglutide
It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes. These self-pay offers can be accessed in multiple ways: Directly through wegovy.com or ozempic.com, where patients can register for savings to be used, with a prescription, at over 70,000 pharmacy locations across the US NovoCare Pharmacy, where prescriptions are sent straight from a healthcare provider and patients receive convenient home delivery or the option to pick up prescriptions at one of over 9,000 CVS retail locations Other participating organizations and select telehealth providers that work directly with Novo Nordisk, such as Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed Semaglutide is the active ingredient in Wegovy and Ozempic and, unlike any other molecule in the GLP-1 class, has FDA-approved medicines with indications for patients with obesity (Wegovy), type 2 diabetes (Ozempic), chronic kidney disease (Ozempic), and cardiovascular disease (Wegovy and Ozempic)
Regular monitoring of pancreatic enzymes is not routinely recommended unless clinical suspicion for pancreatitis exists
Multiagonist unimolecular peptides for obesity and type 2 diabetes: current advances and future directions
This dual mechanism distinguishes Tirzepatide from earlier GLP-1 receptor agonists by targeting complementary metabolic pathways involved in glucose regulation, appetite control and energy homeostasis
